(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/168133 A1

(51) International Patent Classification:
C12N 9/22 (2006.01) *C12N 15/10* (2006.01)
C12N 9/78 (2006.01)

(21) International Application Number:
PCT/US2020/018193

(22) International Filing Date:
13 February 2020 (13.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/805,277	13 February 2019 (13.02.2019)	US
62/805,271	13 February 2019 (13.02.2019)	US
62/852,228	23 May 2019 (23.05.2019)	US
62/852,224	23 May 2019 (23.05.2019)	US
62/931,722	06 November 2019 (06.11.2019)	US
62/931,747	06 November 2019 (06.11.2019)	US
62/941,569	27 November 2019 (27.11.2019)	US
62/966,526	27 January 2020 (27.01.2020)	US

(71) Applicant: **BEAM THERAPEUTICS INC.** [US/US]; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **SLAYMAKER, Ian**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **GAUDELLI, Nicole**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **YU, Yi**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **ZETSCHE, Bernd**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **BORN, David A.**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **LEE, Seung-Joo**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **PACKER, Michael**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US).

(74) Agent: **HUNTER-ENSOR, Melissa**; Greenberg Traurig, LLP, One International Place, Suite 2000, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES




FIG. 1A

(57) Abstract: The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed "ABE8" having unprecedented levels (e.g., >60-70%) of efficiency.

WO 2020/168133 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*